title: PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity.
abstract: Development of vaccines in autoimmune diseases has received wide attention over the last decade. However, many vaccines showed limited clinical efficacy. To enhance vaccine efficacy in infectious diseases, biocompatible and biodegradable polymeric nanoparticles have gained interest as antigen delivery systems. We investigated in mice whether antigen-encapsulated PLGA (poly-lactic-co-glycolic acid), PLGA-TMC (N-trimethyl chitosan) or TMC-TPP (tri-polyphosphate) nanoparticles can also be used to modulate the immunological outcome after nasal vaccination. These three nanoparticles enhanced the antigen presentation by dendritic cells, as shown by increased in vitro and in vivo CD4(+) T-cell proliferation. However, only nasal PLGA nanoparticles were found to induce an immunoregulatory response as shown by enhanced Foxp3 expression in the nasopharynx associated lymphoid tissue and cervical lymph nodes. Nasal administration of OVA-containing PLGA particle resulted in functional suppression of an OVA-specific Th-1 mediated delayed-type hypersensitivity reaction, while TMC-TPP nanoparticles induced humoral immunity, which coincided with the enhanced generation of OVA-specific B-cells in the cervical lymph nodes. Intranasal treatment with Hsp70-mB29a peptide-loaded PLGA nanoparticles suppressed proteoglycan-induced arthritis, leading to a significant reduction of disease. We have uncovered a role for PLGA nanoparticles to enhance CD4(+) T-cell mediated immunomodulation after nasal application. The exploitation of this differential regulation of nanoparticles to modulate nasal immune responses can lead to innovative vaccine development for prophylactic or therapeutic vaccination in infectious or autoimmune diseases.
authors.affiliation: Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, The Netherlands.
authors.forename: Chantal
authors.initials: C
authors.lastname: Keijzer
authors.forename: Bram
authors.initials: B
authors.lastname: Slütter
authors.forename: Ruurd
authors.initials: R
authors.lastname: van der Zee
authors.forename: Wim
authors.initials: W
authors.lastname: Jiskoot
authors.forename: Willem
authors.initials: W
authors.lastname: van Eden
authors.forename: Femke
authors.initials: F
authors.lastname: Broere
mesh_terms: D000281:Administration, Intranasal; D000917:Antibody Formation / Q000187:drug effects*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects; D048271:Chitosan / Q000008:administration & dosage / Q000494:pharmacology*; D006968:Hypersensitivity, Delayed; D019344:Lactic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D053758:Nanoparticles; D011100:Polyglycolic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011122:Polyphosphates / Q000008:administration & dosage / Q000494:pharmacology*; D014612:Vaccines / Q000008:administration & dosage*
chemical_list: C118071:N-trimethyl chitosan chloride; D011122:Polyphosphates; D014612:Vaccines; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D048271:Chitosan; C005692:triphosphoric acid
references.citation: Vaccine. 2005 Mar 7;23(15):1800-3
references.pmid: 15734045
references.citation: FEBS Lett. 2007 Jul 31;581(19):3716-22
references.pmid: 17507013
references.citation: J Immunol. 1999 Nov 15;163(10):5560-5
references.pmid: 10553084
references.citation: Nat Rev Immunol. 2004 Sep;4(9):699-710
references.pmid: 15343369
references.citation: J Immunol Methods. 1999 Feb 1;223(1):77-92
references.pmid: 10037236
references.citation: Nat Med. 2005 Apr;11(4 Suppl):S45-53
references.pmid: 15812489
references.citation: Arthritis Rheum. 1999 Aug;42(8):1628-34
references.pmid: 10446861
references.citation: Nat Rev Immunol. 2005 Dec;5(12):905-16
references.pmid: 16239901
references.citation: Vaccine. 2007 Jan 2;25(1):144-53
references.pmid: 16973248
references.citation: Int Arch Allergy Immunol. 2009;150(3):221-8
references.pmid: 19494519
references.citation: Nat Med. 2002 Sep;8(9):1024-32
references.pmid: 12145647
references.citation: Vaccine. 2003 Mar 7;21(11-12):1250-5
references.pmid: 12559806
references.citation: J Neurol Sci. 1998 Feb 18;155(1):1-12
references.pmid: 9562316
references.citation: Arthritis Rheum. 2004 May;50(5):1665-76
references.pmid: 15146438
references.citation: Science. 2003 Feb 14;299(5609):1057-61
references.pmid: 12522256
references.citation: J Immunol. 1999 Nov 15;163(10):5383-90
references.pmid: 10553063
references.citation: Nat Rev Immunol. 2005 Apr;5(4):318-30
references.pmid: 15803151
references.citation: PLoS One. 2008 Aug 13;3(8):e2954
references.pmid: 18698426
references.citation: Clin Exp Immunol. 1996 Jan;103(1):77-82
references.pmid: 8565291
references.citation: Mucosal Immunol. 2009 May;2(3):254-64
references.pmid: 19262503
references.citation: Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57
references.pmid: 19121350
references.citation: Immunology. 1996 Aug;88(4):493-500
references.pmid: 8881748
references.citation: Arthritis Rheum. 2006 Mar;54(3):854-63
references.pmid: 16508967
references.citation: Crit Rev Immunol. 2003;23(3):199-250
references.pmid: 14584879
references.citation: J Control Release. 2009 Sep 1;138(2):113-21
references.pmid: 19445980
references.citation: Immunology. 1999 Jun;97(2):257-63
references.pmid: 10447740
references.citation: Vaccine. 2010 Apr 26;28(19):3312-7
references.pmid: 20226247
references.citation: Nat Nanotechnol. 2009 Jul;4(7):411-4
references.pmid: 19581891
references.citation: Mucosal Immunol. 2009 Jul;2(4):340-50
references.pmid: 19387433
references.citation: Immunol Rev. 2005 Aug;206:232-59
references.pmid: 16048553
references.citation: J Exp Med. 2009 Jul 6;206(7):1535-47
references.pmid: 19528258
references.citation: Pharm Res. 2009 Jun;26(6):1353-64
references.pmid: 19224344
references.citation: Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1256-62
references.pmid: 9351630
references.citation: J Immunol. 2000 Mar 1;164(5):2711-7
references.pmid: 10679112
references.citation: Vaccine. 2006 May 8;24(19):4201-11
references.pmid: 16446012
references.citation: J Immunol. 2003 Nov 1;171(9):4592-603
references.pmid: 14568933
references.citation: Arthritis Rheum. 2002 Apr;46(4):1109-20
references.pmid: 11953991
references.citation: Vaccine. 2010 Aug 31;28(38):6282-91
references.pmid: 20638455
references.citation: Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):21-42
references.pmid: 11516777
references.citation: Vaccine. 2006 Mar 10;24(11):1847-57
references.pmid: 16288821
references.citation: Clin Exp Allergy. 2008 Mar;38(3):520-8
references.pmid: 18205856
references.citation: Scand J Immunol. 2007 Mar;65(3):276-88
references.pmid: 17309783
references.citation: Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii65-8
references.pmid: 17038477